Core Insights - Labcorp reported strong third-quarter results for 2025, with significant revenue growth and margin improvement driven by its Diagnostics and Central Laboratory businesses [2][3] - The company updated its full-year guidance, reflecting a revenue growth expectation of 7.4% to 8.0% and an adjusted EPS range of $16.15 to $16.50 [6][17] Financial Performance - Total revenue for Q3 2025 was $3.56 billion, an increase of 8.6% from $3.28 billion in Q3 2024 [5][6] - Adjusted EPS rose to $4.18 from $3.50 year-over-year, marking a growth of 19.4% [5][6] - Operating income for Q3 2025 was $396.6 million, compared to $254.1 million in Q3 2024, with an operating margin of 11.1% [5][6] Strategic Developments - Labcorp formed new partnerships with health systems and regional laboratories, enhancing its position as a preferred partner [3][6] - The company signed agreements to acquire assets from Empire City Laboratories and Laboratory Alliance of Central New York, further expanding its capabilities in oncology and clinical testing [7][6] Cash Flow and Capital Allocation - Operating cash flow for Q3 2025 was $387.2 million, up from $277.3 million in Q3 2024 [9] - Free cash flow increased to $280.5 million from $161.5 million year-over-year, primarily driven by higher cash earnings [9][6] - The company repurchased $25 million of common stock and declared a quarterly cash dividend of $0.72 per share [4][6] Guidance and Outlook - The updated full-year guidance includes a revenue growth expectation of 7.4% to 8.0% and an adjusted EPS range of $16.15 to $16.50 [6][17] - Free cash flow guidance was raised to a range of $1.17 billion to $1.29 billion, with the midpoint increased by $25 million [6][17]

Core Insights - Labcorp has received CE-marking for PGDx elio™ tissue complete, making it the first and only test of its kind in the EU for comprehensive solid tumor profiling, significantly enhancing access to personalized cancer care for approximately 2.7 million cancer patients annually in the EU [1][2] Group 1: Product and Regulatory Approval - The PGDx elio™ tissue complete test has been cleared by the U.S. FDA and is now CE-marked under the EU's new In Vitro Diagnostic Regulation (IVDR), supporting guideline-based care for patients with solid tumors [2][3] - The test can analyze multiple biomarkers simultaneously, even from limited tissue samples, which can expedite patient management plans and potentially improve prognoses [2][3] Group 2: Impact on Healthcare and Biopharma - This achievement reflects Labcorp's commitment to advancing precision medicine and improving patient care, setting a new standard for quality and performance in cancer diagnostics [3] - The CE-marking allows for broader laboratory access across the EU, facilitating personalized cancer care and providing biopharma partners with a reliable solution for clinical trials [3][4] Group 3: Company Overview - Labcorp is a global leader in laboratory services, supporting healthcare providers and pharmaceutical companies with diagnostics and drug development, performing over 700 million tests annually [6]